Advancing drug discovery by applying the right medicinal chemistry approaches to deliver high-quality drug candidates
Syngene’s pool of experienced and multi-disciplinary scientists collaborate to efficiently assess hits, optimize compounds, and deliver high quality candidates in the hit-to-lead and lead optimization phases of drug discovery. Our scientists are experts not only in medicinal chemistry but are also well versed in computational chemistry, in vitro and in vivo biology, drug metabolism and pharmacokinetics, as well as toxicology, and are supported by advanced research instrumentation.
The team has a strong track record of having successfully delivered numerous preclinical and clinical candidates in collaboration with clients. Our experience includes therapeutic areas such as oncology, central nervous system, metabolic disorder, pain, inflammation, and autoimmune disorders among others.
Syngene’s medicinal chemistry teams offer the following services:
Drawing on vast scientific experience, our team optimizes hits and identifies the most promising active compounds to progress to the lead optimization stage. Our capabilities include:
- High-throughput synthesis for hit expansion
- Evaluation of hits for potency, selectivity, and drug-likeness
- Conventional and computational chemistry driven design of novel analogs with early absorption, distribution, metabolism, and excretion properties
- Route scouting and focused library synthesis
- In vitro and in vivo screening of compounds for optimization
Using the identified lead compound from the hit-to-lead stage, our scientists work on optimizing and evaluating the leads through various screening studies until a suitable preclinical candidate is ready. Our lead optimization capabilities include:
- Design of hypothesis to optimize hits for desired potency and efficacy
- Multi-parameter optimization of leads
- Optimization studies for potency, selectivity, in vivo efficacy, pharmacokinetic/pharmacodynamic modeling (PK/PD) profile, safety and toxicity profile
- Early scale-up of molecules to support in vivo efficacy and toxicity studies
- Selection of preclinical candidates